These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 36790391)
1. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma. Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391 [TBL] [Abstract][Full Text] [Related]
2. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib. Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299 [TBL] [Abstract][Full Text] [Related]
3. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572 [TBL] [Abstract][Full Text] [Related]
4. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746 [TBL] [Abstract][Full Text] [Related]
5. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
6. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325 [TBL] [Abstract][Full Text] [Related]
7. Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms. Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698 [TBL] [Abstract][Full Text] [Related]
9. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859 [TBL] [Abstract][Full Text] [Related]
10. Combination Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis. Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445 [TBL] [Abstract][Full Text] [Related]
12. Combination Treatment with the BRAF Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573 [TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations. Lu MD; Li H; Nie JH; Li S; Ye HS; Li TT; Wu ML; Liu J Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430869 [TBL] [Abstract][Full Text] [Related]
14. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454 [TBL] [Abstract][Full Text] [Related]
16. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Husain A; Hu N; Sadow PM; Nucera C Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429 [TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer. Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464 [TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699 [TBL] [Abstract][Full Text] [Related]
20. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]